The Role of Iron and Erythropoietin in the Association of Fibroblast Growth Factor 23 with Anemia in Chronic Kidney Disease in Humans

Anemia in chronic kidney disease (CKD) is an almost universal complication of this condition. Fibroblast growth factor 23 (FGF23), a key-player in mineral metabolism, is reportedly associated with anemia and hemoglobin levels in non-dialysis CKD patients. Here, we sought to further characterize this...

Full description

Bibliographic Details
Main Authors: Bernhard Bielesz, Thomas Reiter, Fabian Peter Hammerle, Wolfgang Winnicki, Marija Bojic, Andreas Gleiss, Heidi Kieweg, Franz Ratzinger, Gere Sunder-Plassmann, Rodrig Marculescu
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:Journal of Clinical Medicine
Subjects:
Online Access:https://www.mdpi.com/2077-0383/9/8/2640
_version_ 1797558218479632384
author Bernhard Bielesz
Thomas Reiter
Fabian Peter Hammerle
Wolfgang Winnicki
Marija Bojic
Andreas Gleiss
Heidi Kieweg
Franz Ratzinger
Gere Sunder-Plassmann
Rodrig Marculescu
author_facet Bernhard Bielesz
Thomas Reiter
Fabian Peter Hammerle
Wolfgang Winnicki
Marija Bojic
Andreas Gleiss
Heidi Kieweg
Franz Ratzinger
Gere Sunder-Plassmann
Rodrig Marculescu
author_sort Bernhard Bielesz
collection DOAJ
description Anemia in chronic kidney disease (CKD) is an almost universal complication of this condition. Fibroblast growth factor 23 (FGF23), a key-player in mineral metabolism, is reportedly associated with anemia and hemoglobin levels in non-dialysis CKD patients. Here, we sought to further characterize this association while taking into account the biologically active, intact fraction of FGF23, iron metabolism, and erythropoietin (EPO). Hemoglobin, EPO, iron, and mineral metabolism parameters, including both intact and c-terminal-FGF23 (iFGF23 and cFGF23, respectively) were measured cross-sectionally in 225 non-dialysis CKD patients (stage 1–5, median eGFR: 30 mL/min./1.73m<sup>2</sup>) not on erythropoiesis stimulating agents or intravenous iron therapy. Statistical analysis was performed by multiple linear regression. After adjustment for eGFR and other important confounders, only cFGF23 but not iFGF23 was significantly associated with hemoglobin levels and this association was largely accounted for by iron metabolism parameters. cFGF23 but not iFGF23 was also associated with mean corpuscular hemoglobin (MCH) and mean corpuscular volume (MCV), again in dependence on iron metabolism parameters. Similarly, EPO concentrations were associated with cFGF23 but not iFGF23, but their contribution to the association of cFGF23 with hemoglobin levels was marginal. In pre-dialysis CKD patients, the observed association of FGF23 with hemoglobin seems to be restricted to cFGF23 and largely explained by the iron status.
first_indexed 2024-03-10T17:27:16Z
format Article
id doaj.art-3b23fcc2d0874eeb8611cd7a75933f37
institution Directory Open Access Journal
issn 2077-0383
language English
last_indexed 2024-03-10T17:27:16Z
publishDate 2020-08-01
publisher MDPI AG
record_format Article
series Journal of Clinical Medicine
spelling doaj.art-3b23fcc2d0874eeb8611cd7a75933f372023-11-20T10:07:28ZengMDPI AGJournal of Clinical Medicine2077-03832020-08-0198264010.3390/jcm9082640The Role of Iron and Erythropoietin in the Association of Fibroblast Growth Factor 23 with Anemia in Chronic Kidney Disease in HumansBernhard Bielesz0Thomas Reiter1Fabian Peter Hammerle2Wolfgang Winnicki3Marija Bojic4Andreas Gleiss5Heidi Kieweg6Franz Ratzinger7Gere Sunder-Plassmann8Rodrig Marculescu9Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, 1090 Vienna, AustriaDivision of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, 1090 Vienna, AustriaDivision of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, 1090 Vienna, AustriaDivision of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, 1090 Vienna, AustriaDivision of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, 1090 Vienna, AustriaCenter for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, 1090 Vienna, AustriaDepartment of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, AustriaDepartment of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, AustriaDivision of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, 1090 Vienna, AustriaDepartment of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, AustriaAnemia in chronic kidney disease (CKD) is an almost universal complication of this condition. Fibroblast growth factor 23 (FGF23), a key-player in mineral metabolism, is reportedly associated with anemia and hemoglobin levels in non-dialysis CKD patients. Here, we sought to further characterize this association while taking into account the biologically active, intact fraction of FGF23, iron metabolism, and erythropoietin (EPO). Hemoglobin, EPO, iron, and mineral metabolism parameters, including both intact and c-terminal-FGF23 (iFGF23 and cFGF23, respectively) were measured cross-sectionally in 225 non-dialysis CKD patients (stage 1–5, median eGFR: 30 mL/min./1.73m<sup>2</sup>) not on erythropoiesis stimulating agents or intravenous iron therapy. Statistical analysis was performed by multiple linear regression. After adjustment for eGFR and other important confounders, only cFGF23 but not iFGF23 was significantly associated with hemoglobin levels and this association was largely accounted for by iron metabolism parameters. cFGF23 but not iFGF23 was also associated with mean corpuscular hemoglobin (MCH) and mean corpuscular volume (MCV), again in dependence on iron metabolism parameters. Similarly, EPO concentrations were associated with cFGF23 but not iFGF23, but their contribution to the association of cFGF23 with hemoglobin levels was marginal. In pre-dialysis CKD patients, the observed association of FGF23 with hemoglobin seems to be restricted to cFGF23 and largely explained by the iron status.https://www.mdpi.com/2077-0383/9/8/2640renal insufficiencychronicmineral metabolismanemia
spellingShingle Bernhard Bielesz
Thomas Reiter
Fabian Peter Hammerle
Wolfgang Winnicki
Marija Bojic
Andreas Gleiss
Heidi Kieweg
Franz Ratzinger
Gere Sunder-Plassmann
Rodrig Marculescu
The Role of Iron and Erythropoietin in the Association of Fibroblast Growth Factor 23 with Anemia in Chronic Kidney Disease in Humans
Journal of Clinical Medicine
renal insufficiency
chronic
mineral metabolism
anemia
title The Role of Iron and Erythropoietin in the Association of Fibroblast Growth Factor 23 with Anemia in Chronic Kidney Disease in Humans
title_full The Role of Iron and Erythropoietin in the Association of Fibroblast Growth Factor 23 with Anemia in Chronic Kidney Disease in Humans
title_fullStr The Role of Iron and Erythropoietin in the Association of Fibroblast Growth Factor 23 with Anemia in Chronic Kidney Disease in Humans
title_full_unstemmed The Role of Iron and Erythropoietin in the Association of Fibroblast Growth Factor 23 with Anemia in Chronic Kidney Disease in Humans
title_short The Role of Iron and Erythropoietin in the Association of Fibroblast Growth Factor 23 with Anemia in Chronic Kidney Disease in Humans
title_sort role of iron and erythropoietin in the association of fibroblast growth factor 23 with anemia in chronic kidney disease in humans
topic renal insufficiency
chronic
mineral metabolism
anemia
url https://www.mdpi.com/2077-0383/9/8/2640
work_keys_str_mv AT bernhardbielesz theroleofironanderythropoietinintheassociationoffibroblastgrowthfactor23withanemiainchronickidneydiseaseinhumans
AT thomasreiter theroleofironanderythropoietinintheassociationoffibroblastgrowthfactor23withanemiainchronickidneydiseaseinhumans
AT fabianpeterhammerle theroleofironanderythropoietinintheassociationoffibroblastgrowthfactor23withanemiainchronickidneydiseaseinhumans
AT wolfgangwinnicki theroleofironanderythropoietinintheassociationoffibroblastgrowthfactor23withanemiainchronickidneydiseaseinhumans
AT marijabojic theroleofironanderythropoietinintheassociationoffibroblastgrowthfactor23withanemiainchronickidneydiseaseinhumans
AT andreasgleiss theroleofironanderythropoietinintheassociationoffibroblastgrowthfactor23withanemiainchronickidneydiseaseinhumans
AT heidikieweg theroleofironanderythropoietinintheassociationoffibroblastgrowthfactor23withanemiainchronickidneydiseaseinhumans
AT franzratzinger theroleofironanderythropoietinintheassociationoffibroblastgrowthfactor23withanemiainchronickidneydiseaseinhumans
AT geresunderplassmann theroleofironanderythropoietinintheassociationoffibroblastgrowthfactor23withanemiainchronickidneydiseaseinhumans
AT rodrigmarculescu theroleofironanderythropoietinintheassociationoffibroblastgrowthfactor23withanemiainchronickidneydiseaseinhumans
AT bernhardbielesz roleofironanderythropoietinintheassociationoffibroblastgrowthfactor23withanemiainchronickidneydiseaseinhumans
AT thomasreiter roleofironanderythropoietinintheassociationoffibroblastgrowthfactor23withanemiainchronickidneydiseaseinhumans
AT fabianpeterhammerle roleofironanderythropoietinintheassociationoffibroblastgrowthfactor23withanemiainchronickidneydiseaseinhumans
AT wolfgangwinnicki roleofironanderythropoietinintheassociationoffibroblastgrowthfactor23withanemiainchronickidneydiseaseinhumans
AT marijabojic roleofironanderythropoietinintheassociationoffibroblastgrowthfactor23withanemiainchronickidneydiseaseinhumans
AT andreasgleiss roleofironanderythropoietinintheassociationoffibroblastgrowthfactor23withanemiainchronickidneydiseaseinhumans
AT heidikieweg roleofironanderythropoietinintheassociationoffibroblastgrowthfactor23withanemiainchronickidneydiseaseinhumans
AT franzratzinger roleofironanderythropoietinintheassociationoffibroblastgrowthfactor23withanemiainchronickidneydiseaseinhumans
AT geresunderplassmann roleofironanderythropoietinintheassociationoffibroblastgrowthfactor23withanemiainchronickidneydiseaseinhumans
AT rodrigmarculescu roleofironanderythropoietinintheassociationoffibroblastgrowthfactor23withanemiainchronickidneydiseaseinhumans